Bladder preserving approach for muscle invasive bladder cancer--role of mycobacterium w.
Mycobacterium w (immuvac), a new potent immunomodulator was evaluated as concomitant therapy in the management of muscle invasive bladder cancer along with external beam radiation therapy. There was no residual tumour in all the five patients after two months of therapy. All patients remained disease free for an observation period of more than 2 years.
Chaudhuri
Prabir
P
Department of Radiotherapy, Chittaranjan National Cancer Institute, Calcutta 700026.
Mukhopadhyay
Sharadwat
S
D001428:Bacterial Vaccines / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000187:drug effects / Q000473:pathology* / Q000528:radiation effects; D009161:Mycobacterium; D010865:Pilot Projects; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D001428:Bacterial Vaccines; C080550:Mycobacterium w vaccine